Emergent Biosolutions Inc. (NYSE:EBS) shares saw strong trading volume on Friday . 883,627 shares changed hands during mid-day trading, an increase of 38% from the previous session’s volume of 641,518 shares.The stock last traded at $30.02 and had previously closed at $30.69.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research cut Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 2nd. Cowen and Company reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Sunday, April 17th. Chardan Capital reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Monday, May 2nd. JPMorgan Chase & Co. dropped their price objective on Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Wednesday, June 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $40.00.

The company has a 50-day moving average of $31.40 and a 200-day moving average of $36.29. The company has a market capitalization of $1.20 billion and a PE ratio of 21.30.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by $0.01. During the same quarter in the prior year, the firm posted $0.36 earnings per share. The company earned $101.49 million during the quarter, compared to analysts’ expectations of $111.20 million. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. Equities analysts anticipate that Emergent Biosolutions Inc. will post $1.55 earnings per share for the current fiscal year.

In other Emergent Biosolutions news, Director Louis W. Sullivan sold 9,969 shares of the stock in a transaction on Wednesday, May 11th. The stock was sold at an average price of $39.25, for a total transaction of $391,283.25. Following the transaction, the director now owns 38,469 shares of the company’s stock, valued at approximately $1,509,908.25. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Fuad El-Hibri sold 85,000 shares of the stock in a transaction on Wednesday, May 25th. The stock was sold at an average price of $42.52, for a total value of $3,614,200.00. Following the transaction, the insider now directly owns 1,719,073 shares in the company, valued at approximately $73,094,983.96. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have modified their holdings of the company. Rhumbline Advisers raised its position in shares of Emergent Biosolutions by 6.4% in the fourth quarter. Rhumbline Advisers now owns 41,899 shares of the biopharmaceutical company’s stock worth $1,676,000 after buying an additional 2,505 shares in the last quarter. Bank of Montreal Can raised its position in shares of Emergent Biosolutions by 346.9% in the fourth quarter. Bank of Montreal Can now owns 93,100 shares of the biopharmaceutical company’s stock worth $3,725,000 after buying an additional 72,266 shares in the last quarter. Matarin Capital Management LLC acquired a new position in shares of Emergent Biosolutions during the fourth quarter worth $7,953,000. Cornerstone Capital Management Holdings LLC. raised its position in shares of Emergent Biosolutions by 5.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 57,927 shares of the biopharmaceutical company’s stock worth $2,317,000 after buying an additional 3,227 shares in the last quarter. Finally, US Bancorp DE raised its position in shares of Emergent Biosolutions by 6.9% in the fourth quarter. US Bancorp DE now owns 33,169 shares of the biopharmaceutical company’s stock worth $1,327,000 after buying an additional 2,152 shares in the last quarter.

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.